Skip to Content

Trimetrexate Pregnancy and Breastfeeding Warnings

Trimetrexate is also known as: Neutrexin

Trimetrexate Pregnancy Warnings

Trimetrexate has been assigned to pregnancy category D by the FDA. Trimetrexate has been shown to be teratogenic in animals at doses 1/20 to 1/2 of normal human doses. Fetal toxicities include skeletal, cardiovascular, ocular, and visceral abnormalities. The use of trimetrexate is considered to be contraindicated during pregnancy.

See references

Trimetrexate Breastfeeding Warnings

There are no data on the excretion of trimetrexate into human milk. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, breast-feeding should be discontinued if the mother is treated with trimetrexate.

See references

References for pregnancy information

  1. "Product Information. Neutrexin (trimetrexate)." US Bioscience, West Conshohocken, PA.

References for breastfeeding information

  1. "Product Information. Neutrexin (trimetrexate)." US Bioscience, West Conshohocken, PA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide